BusinessHorizon Pharma plc Announces Availability of PROCYSBI™ (cysteamine bitartrate) in CanadaBy Nasdaq OMXOct 26, 2017, 12:01 PM UTC
BusinessHorizon Pharma plc Announces Four Poster Presentations on PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Capsules at Cystinosis Research Network 2017 Family ConferenceBy Nasdaq OMXJul 14, 2017, 12:00 PM UTC
BusinessHorizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine Delayed-Release Capsules) for the Treatment of Nephropathic CystinosisBy Nasdaq OMXJun 19, 2017, 12:00 PM UTC
BusinessRaptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis PatientsBy Nasdaq OMXSep 7, 2016, 7:30 AM UTC
BusinessRaptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International CongressBy Nasdaq OMXAug 24, 2016, 11:30 AM UTC
BusinessRaptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority ReviewBy Nasdaq OMXMar 21, 2016, 8:05 PM UTC
BusinessRaptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled LevofloxacinBy Nasdaq OMXMar 16, 2016, 11:30 AM UTC
